Back

iRight4Me: individualisation of P2Y12 inihibitors in the realworld practice - an interim report

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Pharmacogenomics, cardio-omics, and cardiovascular drugs Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Doreen Tan

National University of Singapore, Singapore (Singapore)

7 More presentations in this session

Presentation thumbnail
Potential use of pharmacogenetics in cardiology: genome-wide association studies of amiodarone-induced thyroid disorders
Mr S. Rand (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Pharmacogenomics of CRP response to statins: a GIST consortium study
Doctor E. Magavern (London, GB)
Abstract Slides Video
Presentation thumbnail
Evaluating off-target drug effects seen in RCTs using proteomics and mendelian randomisation
Ms J. Brody (Seattle, US)
Abstract Slides Video
Presentation thumbnail
Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients
Doctor J. Azzahhafi (Nieuwegein, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacogenomics, cardio-omics, and cardiovascular drugs

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Real-world implementation of a genotype-guided p2y12-inhibitor de-escalation strategy in acute coronary syndrome patients
thumbnail
Congress Presentation
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
Evaluating the safety and efficacy of ticagrelor vs. clopidogrel following percutaneous coronary intervention in chronic coronary disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources